Nuance pharma announces dosing of first patient in enhance – china phase 3 trial for copd

London and raleigh, n.c., april 10, 2023 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma” or the “company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, nuance pharma, has dosed the first subject in its enhance - china phase 3 trial for the maintenance treatment of chronic obstructive pulmonary disease (“copd”).
VRNA Ratings Summary
VRNA Quant Ranking